Drug Type Colony-stimulating factors |
Synonyms Y-branched pegylated recombinant human granulocyte colony stimulating factor, Y-shaped branched pegylated filgrastim, YPEG-filgrastim + [5] |
Target |
Mechanism CSF-3R agonists(Colony stimulating factor 3 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (30 Jun 2023), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neutropenia | CN | 30 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Febrile Neutropenia | Phase 3 | CN | 16 Oct 2020 | |
Infectious Diseases | Phase 3 | CN | 16 Oct 2020 | |
Breast Cancer | Phase 2 | CN | 01 Dec 2013 | |
Chemotherapy-Induced Febrile Neutropenia | Phase 2 | CN | 01 Dec 2013 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 01 Dec 2013 | |
Chemotherapy-induced nausea and vomiting | Phase 1 | CN | 01 Apr 2010 |